BSI 038
Alternative Names: Anti-CD40 monoclonal antibody - Biosion; BSI-038Latest Information Update: 11 May 2023
At a glance
- Originator Biosion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 May 2023 Biosion has a licensing agreement with Chia Tai Tianqing Pharmaceutical Group to develop and commercialize BSI 038 for Solid tumours in China
- 19 May 2022 BSI 038 is available for licensing as of 19 May 2022. https://www.biosion.com/pipeline/bsi-038/
- 27 Apr 2022 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (IV, Injection)